European Medicines Agency Recommends Seven New Medicines for Approval and Refuses Two Others

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended seven new medicines for marketing authorization and extensions of therapeutic indication for 11 others at its November 2026 meeting. Among the new recommendations are Aumseqa (aumolertinib) for non-small cell lung cancer, Baxfendy (baxdrostat) for insufficiently controlled hypertension, and Zybrivo (sintilimab) for non-squamous non-small cell lung cancer. The CHMP also gave a positive opinion for a new strength of Dapivirine Vaginal Ring, allowing for three-month replacement to reduce HIV-1 infection risk, and recommended extending the use of Gazyvaro (obinutuzumab) for moderate-to-severe active systemic lupus erythematosus. Conversely, the committee confirmed its recommendation to refuse marketing authorization for KemSu (sufentanil / ketamine) for acute pain in children and adolescents, and Meplyffa (arimoclomol citrate) for Niemann-Pick disease type C.

Context

The European Medicines Agency evaluates and approves medicines for use in the European Union. Its Committee for Medicinal Products for Human Use assesses the benefits and risks of new treatments. The recent meeting in November 2026 resulted in recommendations for seven new medicines, reflecting ongoing advancements in medical research.

Why it matters

The European Medicines Agency's recommendations for new medicines can significantly impact patient care and treatment options across Europe. Approvals can lead to improved outcomes for patients with serious conditions, such as cancer and hypertension. The refusal of certain drugs also highlights the agency's commitment to safety and efficacy in medical treatments.

Implications

The approval of new medicines could lead to enhanced treatment protocols and improved patient outcomes in critical health areas. Conversely, the refusal of certain medications may limit options for specific patient populations, particularly in pediatric care. Healthcare providers and patients will need to adapt to these changes in available treatments.

What to watch

Stakeholders will monitor the final decisions from the European Commission regarding the recommended medicines. The market response to these approvals, particularly for cancer treatments and HIV prevention, will be significant. Additionally, the reasons for the refusal of the two drugs may prompt further investigation or alternative treatments.